Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline ...